FATE THERAPEUTICS INC (FATE) Earnings
FATE THERAPEUTICS INC's most recently reported earnings, recent earnings filings (8-K) and headline annual financials, sourced from SEC EDGAR.
Last reported earnings
Nov 5, 2026
From the latest earnings 8-K
Revenue • FY2025
$6.65M
▼ 51.2%YoY
Diluted EPS • FY2025
-$1.15
▲ 29.9%YoY
Reported earnings dates are based on the latest 8-K (Item 2.02) filings. The next earnings date is an estimate projected from FATE's historical reporting pattern, not a company-confirmed date.
Headline financials
| Period | Revenue | Net income | Gross profit | Dil. EPS | Free cash flow | Op. margin | Rev. growth |
|---|---|---|---|---|---|---|---|
| FY2025 | $6.65M | -$136.31M | — | -$1.15 | -$112.04M | -2222.4% | -51.2% |
| FY2024 | $13.63M | -$186.26M | — | -$1.64 | -$123.6M | -1542.6% | -78.5% |
| FY2023 | $63.53M | -$160.93M | — | -$1.64 | -$138.42M | -299.9% | -34.0% |
| FY2022 | $96.3M | -$281.72M | — | -$2.91 | -$283.77M | -320.2% | +72.4% |
Recent earnings filings
| Filed | Form | Accession |
|---|---|---|
| Nov 5, 2026 | 8-K (2.02) | 0001193125-26-448530EDGAR |
| Aug 13, 2026 | 8-K (2.02) | 0001193125-26-347984EDGAR |
| May 13, 2026 | 8-K (2.02) | 0001193125-26-220691EDGAR |
| Feb 26, 2026 | 8-K (2.02) | 0001193125-26-073689EDGAR |
| Nov 13, 2025 | 8-K (2.02) | 0001193125-25-279091EDGAR |
| Aug 12, 2025 | 8-K (2.02) | 0001193125-25-178947EDGAR |
| May 13, 2025 | 8-K (2.02) | 0000950170-25-070280EDGAR |
| Mar 5, 2025 | 8-K (2.02) | 0000950170-25-033507EDGAR |
Never miss a FATE filing.
Get an email when FATE files its next 8-K, Form 4, 10-K or 10-Q with the SEC. Free, no account needed.
Free foreverNo account requiredOne-click unsubscribe
Data as of Nov 8, 2026Source: SEC EDGAR.